Bank of New York Mellon Corp Increases Stock Position in Edwards Lifesciences Corporation $EW

Bank of New York Mellon Corp grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 8.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,010,227 shares of the medical research company’s stock after purchasing an additional 1,423,365 shares during the quarter. Bank of New York Mellon Corp owned approximately 3.24% of Edwards Lifesciences worth $1,478,425,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of EW. Econ Financial Services Corp purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in shares of Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares during the period. OMERS ADMINISTRATION Corp boosted its holdings in shares of Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $300,000. Finally, Ninety One UK Ltd grew its position in shares of Edwards Lifesciences by 14.0% in the third quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock valued at $615,050,000 after purchasing an additional 969,030 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on EW shares. Wells Fargo & Company set a $100.00 price target on Edwards Lifesciences in a research note on Thursday, December 18th. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. The Goldman Sachs Group restated a “buy” rating and issued a $108.00 target price on shares of Edwards Lifesciences in a report on Friday, January 9th. Citigroup reaffirmed a “buy” rating and set a $101.00 price target (up previously from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Finally, Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $96.82.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 57,824 shares of company stock valued at $4,863,323 in the last quarter. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 0.8%

NYSE EW opened at $83.59 on Wednesday. The stock has a market cap of $48.51 billion, a P/E ratio of 36.03, a PEG ratio of 3.22 and a beta of 0.95. The company’s fifty day simple moving average is $84.97 and its 200-day simple moving average is $80.93. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.